Compare Panacea Biotech with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs NEULAND LABS - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH NEULAND LABS PANACEA BIOTECH/
NEULAND LABS
 
P/E (TTM) x 15.8 64.1 24.7% View Chart
P/BV x 6.2 4.8 127.3% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   NEULAND LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
NEULAND LABS
Mar-20
PANACEA BIOTECH/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs354754 46.9%   
Low Rs138247 55.9%   
Sales per share (Unadj.) Rs74.6594.5 12.5%  
Earnings per share (Unadj.) Rs6.712.6 52.9%  
Cash flow per share (Unadj.) Rs15.537.0 41.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs57.2553.4 10.3%  
Shares outstanding (eoy) m61.2512.83 477.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.8 391.7%   
Avg P/E ratio x36.839.6 92.9%  
P/CF ratio (eoy) x15.913.5 117.4%  
Price / Book Value ratio x4.30.9 475.3%  
Dividend payout %015.8 0.0%   
Avg Mkt Cap Rs m15,0616,421 234.6%   
No. of employees `0002.31.3 180.5%   
Total wages/salary Rs m1,4711,236 119.0%   
Avg. sales/employee Rs Th1,973.65,949.4 33.2%   
Avg. wages/employee Rs Th635.6963.8 66.0%   
Avg. net profit/employee Rs Th176.8126.4 139.8%   
INCOME DATA
Net Sales Rs m4,5677,627 59.9%  
Other income Rs m4539 115.3%   
Total revenues Rs m4,6127,666 60.2%   
Gross profit Rs m2,0301,019 199.2%  
Depreciation Rs m540313 172.6%   
Interest Rs m1,048216 485.9%   
Profit before tax Rs m486529 91.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m77367 21.0%   
Profit after tax Rs m409162 252.4%  
Gross profit margin %44.413.4 332.7%  
Effective tax rate %15.969.4 22.9%   
Net profit margin %9.02.1 421.5%  
BALANCE SHEET DATA
Current assets Rs m2,4155,152 46.9%   
Current liabilities Rs m9,0773,576 253.8%   
Net working cap to sales %-145.920.7 -706.3%  
Current ratio x0.31.4 18.5%  
Inventory Days Days65105 61.9%  
Debtors Days Days7191 78.0%  
Net fixed assets Rs m8,3333,969 210.0%   
Share capital Rs m61129 47.5%   
"Free" reserves Rs m3,4436,971 49.4%   
Net worth Rs m3,5047,100 49.4%   
Long term debt Rs m461774 59.6%   
Total assets Rs m13,75512,310 111.7%  
Interest coverage x1.53.5 42.4%   
Debt to equity ratio x0.10.1 120.8%  
Sales to assets ratio x0.30.6 53.6%   
Return on assets %10.63.1 345.2%  
Return on equity %11.72.3 511.4%  
Return on capital %38.79.5 409.0%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,2035,187 23.2%   
Fx outflow Rs m4671,593 29.3%   
Net fx Rs m7363,594 20.5%   
CASH FLOW
From Operations Rs m1,049573 182.9%  
From Investments Rs m-54-487 11.0%  
From Financial Activity Rs m-1,011-55 1,845.6%  
Net Cashflow Rs m-2033 -60.4%  

Share Holding

Indian Promoters % 74.5 36.3 205.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 63.7 0.9%  
FIIs % 1.3 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 63.7 37.0%  
Shareholders   10,259 12,705 80.7%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 7, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS